Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Artivion relies on product pipeline as growth engine and targets around US$500m revenue for 2026

At the Canaccord conference Artivion said revenue for 2025 was just above US$400m and it is forecasting about US$500m for 2026, with EBITDA of roughly US$90m in 2025. PMA approvals for AMDS and NEXUS strengthen the pipeline; the US launch of NEXUS is planned for January 2026. Higher R&D spending, inventory build-up and integration costs are expected in 2026 before free cash flow improves significantly later. Management sees limited competition in the PMA-protected niche markets and aims for double-digit revenue growth with disproportionately higher EBITDA growth. » More on de.investing.com
Artivion shareholders confirm board nominees and approve compensation

At the annual general meeting, shareholders elected all of Artivion’s nominated directors and voted in a non-binding resolution to approve the board’s compensation. Shareholders also provisionally ratified Ernst & Young as the independent auditor for fiscal year 2026. Artivion reported Q1 earnings per share of $0.08 and revenue of $116.3 million, but cut its full-year revenue and adjusted EBITDA guidance because of weaker stent‑graft sales. Analysts lowered price targets but mostly maintained positive ratings; the stock traded at $22.98 before the meeting and is down significantly year‑on‑year. » More on de.investing.com
Artivion cuts annual guidance and buys Endospan – stock plunges nearly 29%

Artivion reported Q1 results with revenue and earnings metrics above estimates but sharply lowered its 2026 revenue and adjusted EBITDA guidance. The company exercised the purchase option for Endospan following FDA approval of NEXUS and plans a net upfront payment of about $135 million plus up to $200 million in milestone payments, raising short-term financing concerns. Several analysts cut their price targets, adjusted EBITDA slightly missed consensus, and the stock fell to a 52-week low. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Artivion has already paid €0.39 in dividends. The last payout was in May.

Fundamentals

Metric	Value
Market capitalization	€747.25K
Number of shares	55.29K
52-week high/low	€23.30 - €13.39
Dividend yield	1.90%
Dividends TTM	€0.39
Beta	1.40
P/E ratio	61.86
PEG ratio	0.01
P/B ratio	1.61
P/S ratio	0.00

Company profile

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. Artivion Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.